Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080
Debt
Debt-to-Equity RatioN/A
Current Ratio3.94
Quick Ratio3.94
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.14 million
Price / Sales35.41
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-32.33
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-37,120,000.00
Net Margins-1,139.25%
Return on Equity-471.25%
Return on Assets-91.77%
Miscellaneous
Employees59
Outstanding Shares26,040,000
Novan (NASDAQ:NOVN) Frequently Asked Questions
What is Novan's stock symbol?
Novan trades on the NASDAQ under the ticker symbol "NOVN."
How were Novan's earnings last quarter?
Novan (NASDAQ:NOVN) announced its quarterly earnings results on Tuesday, March, 27th. The company reported ($0.51) earnings per share (EPS) for the quarter. The company had revenue of $0.62 million for the quarter. Novan had a negative net margin of 1,139.25% and a negative return on equity of 471.25%. View Novan's Earnings History.
When is Novan's next earnings date?
What price target have analysts set for NOVN?
3 analysts have issued 1-year target prices for Novan's stock. Their predictions range from $6.00 to $14.00. On average, they expect Novan's stock price to reach $10.00 in the next twelve months. View Analyst Ratings for Novan.
Who are some of Novan's key competitors?
Some companies that are related to Novan include Ocular Therapeutix (OCUL), CTI BioPharma (CTIC), Biofrontera (BFRA), Selecta Biosciences (SELB), Athersys (ATHX), Kindred Biosciences (KIN), Marinus Pharmaceuticals (MRNS), Kadmon (KDMN), CELYAD SA/ADR (CYAD), MannKind (MNKD), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Avadel Pharmaceuticals (AVDL), AVEO Pharmaceuticals (AVEO), Cue Biopharma (CUE) and Sierra Oncology (SRRA).
Who are Novan's key executives?
Novan's management team includes the folowing people:
- Mr. Robert Alexander Ingram, Exec. Chairman (Age 76)
- Mr. G. Kelly Martin, CEO & Director (Age 59)
- Dr. Nathan Stasko Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, CFO, Chief Bus. Officer, Exec. VP & Company Sec. (Age 61)
- Mr. Andrew Novak, VP & Chief Accounting Officer
When did Novan IPO?
(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Novan been receiving favorable news coverage?
News articles about NOVN stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novan earned a news impact score of 0.15 on Accern's scale. They also assigned news headlines about the company an impact score of 44.68 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Novan's major shareholders?
Novan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (2.09%) and CVI Holdings LLC (1.77%). Company insiders that own Novan stock include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.
Which major investors are buying Novan stock?
NOVN stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC and CVI Holdings LLC. Company insiders that have bought Novan stock in the last two years include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Insider Buying and Selling for Novan.
How do I buy shares of Novan?
Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novan's stock price today?
One share of NOVN stock can currently be purchased for approximately $2.91.
How big of a company is Novan?
Novan has a market capitalization of $75.51 million and generates $2.14 million in revenue each year. Novan employs 59 workers across the globe.
How can I contact Novan?
Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]
MarketBeat Community Rating for Novan (NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
